The FDA has spent years approving individual robotic surgical systems one at a time, without ever writing down, in one place, what it actually wants to see. That changed this week.
On September 25, the agency released its first comprehensive draft guidance for robotically-assisted surgical devices, the teleoperated, software-controlled systems that help surgeons position and control instruments during open, minimally invasive and endoluminal procedures.
Deadline to comment on the draft guidance before FDA begins work on a final version.
Three subassemblies, one submission
The guidance breaks these systems into three parts familiar to anyone who has watched one operate: an operator console where the surgeon views the surgical field and directs movement, a patient-side cart that carries the instruments, and a tower that houses imaging and processing hardware. For each, FDA lays out the nonclinical testing, clinical evidence and labeling it expects in a premarket submission, covering system architecture, motion control, safety mechanisms and performance testing.
The bigger question is autonomy
This guidance covers systems still controlled directly by a surgeon's hands. It does not resolve the harder question hanging over the field: how to evaluate systems that operate with less human input. FDA scheduled a separate two-day workshop for December 2 and 3, focused specifically on autonomous and remotely operated robotic devices, and positioned it as the venue for the technical, safety and regulatory questions this guidance leaves open.
This is the first time FDA has written down, in one document, what a premarket submission for a surgical robot should contain. Uncertainty over evidence expectations has historically meant expensive rework late in a program. A common playbook does not guarantee an easier bar, but it makes the bar visible before a company files.
What to watch
Watch the comment period, which closes November 24, and the December workshop, which is likely to signal where FDA is headed on autonomous systems specifically. Also watch how other regulators, including the UK's National Commission and the EU's evolving MDR and AI Act interaction, position their own frameworks against the US approach, since global manufacturers rarely get to choose only one.
Surgical robotics has moved from a handful of specialist categories to a crowded field of new entrants. A shared evidence framework helps everyone compete on the same terms, but it also raises the floor. Companies that treat this guidance as a checklist to clear will do fine. Companies that treat it as a signal of where the category is headed will do better.